Background: The impact of different levels of tracer uptake on improvements of left-ventricular (LV) function was analyzed in patients treated by intracoronary bone marrow cell (BMC) transplantation.

Methods And Results: Thirty-one patients with irreversible damage after their first acute myocardial infarction (MI), as confirmed by sestamibi single-photon emission computed tomography (MIBI SPECT)/fluorodeoxyglucose positron emission tomography (FDG PET), underwent high-dose (1 x 10(8) cells) BMC transplantation, whereas 31 similar patients were randomly integrated into a control group. In 11 BMC-treated patients with very low sestamibi uptake at less than 30% of maximum in the infarcted area, the mean left-ventricular ejection fraction (LVEF) improved after 3 months of follow-up by 3% only, and mean end-diastolic/end-systolic volumes (EDV/ESV) enlarged by 10/1 mL (P = NS vs controls). In 20 BMC-treated patients with higher sestamibi uptake in the range of 31% to 50% of maximum, LVEF improved by 7%, and EDV/ESV decreased by 5/12 mL (P < .05 vs BMC-treated subgroup with low MIBI uptake and controls). No similar categorization was seen in the control group: in patients with higher sestamibi uptake or very low uptake, the LVEF increased by 2% and 3% only, and the EDV/ESV enlarged in both subgroups by 12/4 mL and 12/2 mL, respectively (P = NS).

Conclusions: Our results suggest the capability of SPECT/PET imaging to select patients who will receive the maximum benefit from BMC therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nuclcard.2008.02.016DOI Listing

Publication Analysis

Top Keywords

sestamibi uptake
12
intracoronary bone
8
bone marrow
8
marrow cell
8
control group
8
bmc-treated patients
8
lvef improved
8
edv/esv enlarged
8
patients higher
8
higher sestamibi
8

Similar Publications

Purpose: Parathyroid carcinoma (PC) is an extremely rare disease, typically presenting with marked elevations of serum calcium concentrations and associated with significantly increased parathyroid hormone (PTH) levels. Although it progresses slowly, approximately25% of PC patients have lung metastases. In the present study, we aimed to evaluate the role of technetium-99m methoxy isobutyl isonitrile (Tc-99m-MIBI; sestamibi) SPECT/CT scintigraphy in the preoperative localization of parathyroid adenomas, incidental metastases findings of PC, and ectopic parathyroid tissue.

View Article and Find Full Text PDF

Molecular breast imaging (MBI) is a functional imaging modality that utilizes technetium 99m sestamibi radiotracer uptake to evaluate the biology of breast tumors. Molecular breast imaging can be a useful tool for supplemental screening of women with dense breasts, for breast cancer diagnosis and staging, and for evaluation of treatment response in patients with breast cancer undergoing neoadjuvant systemic therapy. In addition, MBI is useful in problem-solving when mammography and US imaging are insufficient to arrive at a definite diagnosis and for patients who cannot undergo breast MRI.

View Article and Find Full Text PDF

Unknown Case: Asymmetric Breast Uptake on Sestamibi Scan.

J Breast Imaging

November 2024

Department of Radiology, Weill Cornell Medicine, New York, NY, USA.

View Article and Find Full Text PDF
Article Synopsis
  • This study assesses the effectiveness of prone SPECT imaging with [Tc]Tc-sestamibi compared to Molecular Breast Imaging (MBI) in predicting treatment response in women with locally advanced breast cancer (LABC).
  • It involved 18 patients who underwent SPECT scans shortly after and 90 minutes post-injection, along with MBI, to analyze tumor characteristics like wash-out rates and standardized uptake values.
  • Results indicated that early SPECT provided useful semi-quantitative data comparable to MBI, though further research with broader clinical parameters is necessary to determine the clinical implications of these findings.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!